Trading · Founded 1996 · www.achyuthealthcare.com · BSE 543499 · · ISIN INE0K1401020
No Notes Added Yet
Business
Achyut Healthcare Ltd. operates in the Trading sector, specifically within the healthcare industry in India. As a trading company, its core business model involves procuring healthcare-related products from manufacturers or suppliers and distributing them to various customers, which could include hospitals, clinics, pharmacies, or other distributors. The company primarily makes money through the margin achieved by buying products at wholesale prices and selling them at a higher price, covering operational costs and generating profit from the differential. The specific products traded could range from pharmaceuticals, medical devices, diagnostic kits, surgical supplies, or other healthcare consumables.
Revenue Mix
Specific details on Achyut Healthcare Ltd.'s key business segments or a detailed revenue mix are not publicly available. However, based on its sector, potential segments could include:
Pharmaceutical Trading (distribution of medicines)
Medical Device Trading (distribution of equipment and instruments)
Surgicals & Consumables Trading (distribution of disposables and supplies)
Without further information, it is assumed their revenue is predominantly derived from the sale of traded goods.
Industry
The healthcare trading industry in India is highly competitive and often fragmented, characterized by numerous small to medium-sized players alongside larger, established distributors. The market relies heavily on robust supply chain networks, efficient logistics, and strong relationships with both manufacturers and end-users. Achyut Healthcare Ltd. likely positions itself by focusing on specific geographical regions, product categories, or customer segments, aiming for efficient inventory management and timely delivery to gain market share. Its competitive standing against peers would depend on its distribution reach, product portfolio, pricing strategy, and operational efficiency.
MOAT
For a trading company, achieving a strong competitive advantage (moat) can be challenging. Achyut Healthcare Ltd. may possess a moderate moat if it has:
Scale and Network: An extensive distribution network or exclusive agreements with key manufacturers/suppliers.
Operational Efficiency: Highly efficient logistics and inventory management systems that reduce costs and improve delivery times.
Relationships: Strong, long-standing relationships with key customers (e.g., hospital chains) or reliable suppliers built on trust and consistent service.
However, trading businesses generally face lower switching costs for customers and suppliers, making deep, durable moats less common without significant differentiation or proprietary technology.
Growth Drivers
Key factors that could drive growth for Achyut Healthcare Ltd. over the next 3-5 years include:
Increasing Healthcare Expenditure: Growing public and private healthcare spending in India due to population growth, rising incomes, and greater health awareness.
Healthcare Infrastructure Expansion: The continuous expansion of hospitals, clinics, and diagnostic centers across India, increasing demand for healthcare products.
Government Initiatives: Policy support and schemes aimed at improving healthcare access and affordability (e.g., Ayushman Bharat) can stimulate demand.
Product Portfolio Expansion: Adding new product lines, especially in high-growth therapeutic areas or advanced medical technologies.
Geographic Expansion: Extending its distribution network into new regions or underserved markets within India.
Risks
Achyut Healthcare Ltd. faces several risks inherent to the trading and healthcare sectors:
Inventory and Price Volatility: Risk of product obsolescence, damage, or price fluctuations (especially for imported goods subject to currency rates) impacting margins.
Supply Chain Disruptions: Dependency on manufacturers and logistics, making it vulnerable to supply chain bottlenecks, quality issues, or delays.
Intense Competition: The fragmented nature of the trading market can lead to pricing pressures and margin erosion.
Regulatory Changes: Changes in healthcare product regulations, drug pricing policies, import/export duties, or distribution guidelines can impact operations.
Credit Risk: Risk of non-payment or delayed payments from customers, especially smaller healthcare providers.
Economic Downturns: Reduced healthcare spending during economic slowdowns could negatively affect demand.
Management & Ownership
Specific details on the management team and ownership structure are not readily available. For a company of this nature, it is common for it to be promoter-led, with significant ownership held by the founding family or individuals. The quality of management would be critical, particularly their experience in procurement, logistics, regulatory compliance within the Indian healthcare sector, and financial discipline. Transparency regarding management background, board composition, and corporate governance practices would be important for external assessment.
Outlook
Achyut Healthcare Ltd. operates in the promising Indian healthcare market, which is poised for long-term growth driven by demographic trends and increased healthcare access. As a trading entity, it stands to benefit from this expanding demand by efficiently connecting product supply with market needs. The bull case hinges on the company's ability to forge strong supplier relationships, build an efficient distribution network, manage inventory effectively, and strategically expand its product portfolio and geographic reach to capitalize on India's evolving healthcare landscape. The bear case, however, acknowledges the inherent challenges of the trading business, including thin margins due to intense competition, vulnerability to supply chain and regulatory risks, and potential for price volatility. Sustained success will depend on disciplined operational execution and adept navigation of a dynamic and competitive market.
| #(Fig in Cr.) | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Net Sales | 0 | 1 | 3 | 2 | 4 | 3 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 1 | 3 | 2 | 5 | 3 |
| Total Expenditure | 0 | 1 | 3 | 2 | 4 | 3 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjustments | 0 | -0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | 0 | 0 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1 | 0 | 0 | 4 | 3 | 6 | 3 | 12 | 12 |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Total Income | 1 | 0 | 0 | 4 | 3 | 7 | 4 | 12 | 13 |
| Total Expenditure | 1 | 0 | 0 | 4 | 3 | 6 | 3 | 11 | 12 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Adjusted Earnings Per Share | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 300% | 59% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | -100% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 7% | 19% | NA% | NA% |
| ROE Average | 1% | 2% | 2% | 1% |
| ROCE Average | 1% | 2% | 2% | 4% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 0 | 0 | 0 | 9 | 15 | 31 | 31 | 35 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -0 | -0 | -0 | -0 | -0 | -0 | 1 | 1 |
| Total Current Liabilities | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 |
| Total Liabilities | 0 | 0 | 0 | 10 | 15 | 31 | 34 | 38 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Other Non-Current Assets | 0 | 0 | 0 | 2 | 5 | 9 | 23 | 29 |
| Total Current Assets | 0 | 0 | 0 | 8 | 10 | 21 | 10 | 8 |
| Total Assets | 0 | 0 | 0 | 10 | 15 | 31 | 34 | 38 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 1 |
| Cash Flow from Operating Activities | -0 | -0 | 0 | -7 | -0 | -0 | -4 | 1 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | -2 | -5 | -15 | -1 | -2 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 9 | 5 | 16 | -0 | 3 |
| Net Cash Inflow / Outflow | -0 | -0 | 0 | 0 | -0 | 0 | -6 | 2 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.02 | 0.02 | 0.01 |
| CEPS(Rs) | -0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.02 | 0.03 | 0.02 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.2 | 0.21 | 0.25 | 0.64 | 0.74 | 1.31 | 1.33 | 1.45 |
| Core EBITDA Margin(%) | 2.05 | 2.3 | 4.15 | -0.95 | -10.16 | 0.43 | -5.03 | 1.51 |
| EBIT Margin(%) | 2.11 | 5.75 | 4.73 | 2.5 | 11.56 | 12.13 | 22.6 | 3.56 |
| Pre Tax Margin(%) | 2.01 | 5.66 | 4.67 | 2.48 | 11.48 | 12.08 | 21.34 | 3.24 |
| PAT Margin (%) | -2.19 | 4.19 | 3.89 | 1 | 8.58 | 8.18 | 16.89 | 2.72 |
| Cash Profit Margin (%) | -2.19 | 4.19 | 3.89 | 1.13 | 8.81 | 8.32 | 19.5 | 3.91 |
| ROA(%) | -6.33 | 5.58 | 2.88 | 0.77 | 1.83 | 2.17 | 1.58 | 0.88 |
| ROE(%) | -7.46 | 6.91 | 4.62 | 0.86 | 1.96 | 2.22 | 1.66 | 0.95 |
| ROCE(%) | 7.21 | 9.48 | 5.61 | 2.17 | 2.64 | 3.29 | 2.22 | 1.25 |
| Receivable days | 53.27 | 145.63 | 300.74 | 21.45 | 31.69 | 20.4 | 105.12 | 43.9 |
| Inventory Days | 0 | 0 | 128.36 | 10.04 | 30.05 | 11.11 | 14.55 | 9.74 |
| Payable days | 15.87 | 71.21 | 225.13 | 33.93 | 63.77 | 16.29 | 84.64 | 43.14 |
| PER(x) | 0 | 0 | 0 | 343.65 | 221.01 | 174.35 | 148.86 | 402.29 |
| Price/Book(x) | 0 | 0 | 0 | 1.52 | 3.52 | 2.84 | 2.46 | 3.63 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.32 | 0.71 | 0.84 | 3.36 | 18.87 | 14.19 | 22.94 | 10.69 |
| EV/Core EBITDA(x) | 15.25 | 12.38 | 17.7 | 127.74 | 160 | 115.73 | 91.03 | 224.71 |
| Net Sales Growth(%) | 0 | -49.94 | -18.39 | 1385.04 | -33.43 | 127.67 | -50.34 | 280.47 |
| EBIT Growth(%) | 0 | 36.17 | -32.81 | 683.68 | 208.11 | 138.88 | -7.46 | -39.98 |
| PAT Growth(%) | 0 | 195.89 | -24.16 | 279.57 | 473.7 | 117.26 | 2.47 | -38.66 |
| EPS Growth(%) | 0 | 195.89 | -24.17 | -73.25 | 313.72 | 80.8 | 2.82 | -40.18 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 5.46 | 4.12 | 1.7 | 9.13 | 12.68 | 106.64 | 6.95 | 4.59 |
| Quick Ratio(x) | 5.46 | 4.12 | 1.32 | 8.98 | 12.29 | 106.36 | 6.82 | 4.34 |
| Interest Cover(x) | 20.14 | 64 | 79.05 | 168.5 | 155.75 | 256.59 | 17.93 | 10.99 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.77 | 44.8 | 44.8 | 46.11 | 46.11 | 46.38 | 47.07 | 47.71 | 47.4 | 47.4 |
| FII | 0 | 0 | 0 | 6.14 | 8.14 | 6.14 | 5.26 | 5.26 | 5.13 | 5.13 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 46.23 | 55.2 | 55.2 | 47.75 | 45.75 | 47.49 | 47.67 | 47.03 | 47.47 | 47.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.75 | 0.75 | 0.75 | 0.78 | 10.86 | 10.92 | 11.09 | 11.24 | 11.44 | 11.44 |
| FII | 0 | 0 | 0 | 0.1 | 1.92 | 1.45 | 1.24 | 1.24 | 1.24 | 1.24 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.65 | 0.93 | 0.93 | 0.8 | 10.78 | 11.19 | 11.23 | 11.08 | 11.46 | 11.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.4 | 1.68 | 1.68 | 1.68 | 23.56 | 23.56 | 23.56 | 23.56 | 24.14 | 24.14 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +300% | +59% | — | — |
| Operating Profit CAGR | 0% | — | — | — |
| PAT CAGR | -100% | — | — | — |
| Share Price CAGR | +7% | +19% | — | — |
| ROE Average | +1% | +2% | +2% | +1% |
| ROCE Average | +1% | +2% | +2% | +4% |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.77 | 44.8 | 44.8 | 46.11 | 46.11 | 46.38 | 47.07 | 47.71 | 47.4 | 47.4 |
| FII | 0 | 0 | 0 | 6.14 | 8.14 | 6.14 | 5.26 | 5.26 | 5.13 | 5.13 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 46.23 | 55.2 | 55.2 | 47.75 | 45.75 | 47.49 | 47.67 | 47.03 | 47.47 | 47.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.75 | 0.75 | 0.75 | 0.78 | 10.86 | 10.92 | 11.09 | 11.24 | 11.44 | 11.44 |
| FII | 0 | 0 | 0 | 0.1 | 1.92 | 1.45 | 1.24 | 1.24 | 1.24 | 1.24 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.65 | 0.93 | 0.93 | 0.8 | 10.78 | 11.19 | 11.23 | 11.08 | 11.46 | 11.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.4 | 1.68 | 1.68 | 1.68 | 23.56 | 23.56 | 23.56 | 23.56 | 24.14 | 24.14 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.